ZURICH, Sept 21 (Reuters) - Novartis has bought gene therapy specialist Arctos Medical to boost its efforts finding treatments for patients with severe vision loss, the Swiss company said on Tuesday.
The acquisition, for an undisclosed amount, underscores Novartis' commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments